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The use of enzyme catalysis to power of micro- and nanomotors exploiting biocompatible fuels 
has opened new ventures for biomedical applications such as the active transport and delivery 
of specific drugs to the site of interest. Here, urease powered nanomotors (nanobots) for the 
doxorubicin (Dox) anti-cancer drug loading, release and efficient delivery to cells are presented. 
These mesoporous silica-based core-shell nanobots are able to self-propel in ionic media, as 
confirmed by optical tracking and dynamic light scattering analysis. A four-fold increase in 




Furthermore, the use of Dox-loaded nanobots presents an enhanced anti-cancer efficiency 
towards HeLa cells, which arises from a synergistic effect of the enhanced drug release and the 
ammonia produced at high concentrations of urea substrate. A higher content of Dox inside 
HeLa cells is detected after 1, 4, 6 and 24 hours incubation with active nanobots compared to 
passive dox-loaded nanoparticles. The improvement in drug delivery efficiency achieved by 
enzyme-powered nanobots may hold potential towards their use in future biomedical 
applications such as the substrate-triggered release of drugs in target locations. 
 
1. Introduction 
The design of active and smart systems capable of bypassing side effects while increasing 
drug efficacy is a long-standing challenge in biomedicine and nanotechnology. Such systems 
require a number of characteristics, namely biocompatibility, biodegradability, and circulation 
stability. Furthermore, their maneuvering for full motion control is required to be able to deliver 
cargo at the defined locations, minimizing undesirable effects in the bystander tissues.[1–3]  
Traditional drug delivery systems rely on the use of passive nanoparticles (i.e. without 
propulsion capabilities), which has been reported to have low efficacy.[2] In contrast, in the last 
decade, researchers have developed micro-/nanoparticles able to self-propel in aqueous media, 
which have potential as novel and active drug delivery vehicles.[4–9] Propulsion at the micro-
/nanoscale can be achieved by a multitude of approaches, such as the use of ultra-sound 
waves,[10] light,[11,12] magnetic fields,[13,14] by coupling motile cells to particles[15–21] or by 
catalytic decomposition of a chemical substrate.[22–25] Since catalytic micro-/nanomotors were 
primarily based on the use of toxic fuels, such as hydrogen peroxide[26–29] and hydrazine,[30] the 
potential of these synthetic motors in the biomedical field demanded the quest for alternative 
biocompatible fuel sources. Alternatively, the use of enzymes as biological catalytic units to 
power the motion of varied micro-/nanostructures has been reported.[22,31–37] Enzyme catalysis 




provide a more versatile library of relevant, bioavailable and biocompatible substrates to be 
used as fuels upon demand of the target application. 
The self-propulsion abilities of these synthetic motors may bring distinct improvements when 
compared to passive drug carriers. Namely, self-propulsion provides the vehicles with 
continuous driving force, aiding their transport across biological tissues.[5,38] In addition, upon 
regulation of the motors’ speed, cell targeting and internalization phenomena could be 
modulated, providing enhanced control and tunability of the drug delivery system.[39] 
Considerable efforts have been applied to the fabrication of micro-/nanomotors that fulfil the 
requirements for ideal drug delivery vehicles.[31,32,40–42] Mesoporous silica, specifically the 
Mobil Composition of Matter No. 41 (MCM-41) type, is a widely studied material for 
biomedical applications which is approved for clinical use by the FDA.[43,44] Previous research 
on this type of silica revealed it to be biocompatible, which in addition to its high cargo loading 
capacity, tunability, and easy surface chemistry make it an optimal chassis for drug delivery 
vehicles.[44] Our group previously demonstrated the self-propulsion of micro- and 
nanostructures based on MCM-41 silica and their coupling with enzymes to engineer 
nanomotors powered by the bio-catalytic conversion of urea and glucose, aiming at their 
application in the biomedical field.[31,32,45,46] However, the benefits in drug delivery based on 
active particles compared with passive particles, as well as their motion in physiological media 









Scheme 1. Schematic illustration of the fabrication and drug delivery system features of the 
urease nanobots. Fabrication of the nanobot mesoporous structure using 
cetyltrimethylammonium bromide (CTAB) and tetraethylorthosilicate (TEOS), and further 
modification with amine groups using 3-aminopropyltriethoxysilane (APTES) (a). Loading of 
Doxorubicin (Dox) onto the mesoporous shell, urease attachment and enhanced drug release 
provoked by self-propulsion due to the presence of urea (b). 
 
Herein, we present the facile fabrication of enzymatic nanomotors, dubbed nanobots, 
comprised of a solid silica core and a mesoporous silica shell (Scheme 1a). The shell was coated 
with urease enzymes which allows to harness chemical energy and convert it into mechanical 
work even in ionic media (PBS buffer solution), an important characteristic for their potential 
use in biomedical applications. Furthermore, the mesoporous shell provides high loading 
capacity, enabling the retention of the anti-cancer water-soluble drug Doxorubicin (Dox) 
(Scheme 1b) and its active transport towards cancer cells. The presence and release of Dox 
inside the cell is quantified and imaged by fluorescence microscopy.  
 
2. Results and discussion 
 





Solid silica spheres, synthesized using a modified Stöber method,[47] were used as core for the 
fabrication of core-shell nanoparticles (MSNP), as depicted in Scheme S1. The mesoporous 
silica shell was grown based on previously reported approaches that provide stability and low 
aggregation in solution.[31] We used cetyltrimethylammonium bromide (CTAB) as porogenic 
agent and triethanolamine (TEOA) as a base catalyst (see experimental details in the Methods 
section). The MSNP were functionalized with 3-aminopropyltriethoxysilane (APTES) to obtain 
nanoparticles with free amine groups on the surface (MSNP-NH2), which were used to 
covalently attach urease to the nanoparticles using glutaraldehyde (GA) as linker molecule, thus 
yielding urease nanobots. The fabrication process was characterized by scanning electron 
microscopy (SEM) and dynamic light scattering (DLS). Figure 1a displays SEM micrograph 
of MSNP, revealing the good monodispersity of the MSNPs (Ø = 344 ± 3, average size ± 
standard error of mean (SE), N = 60). DLS analysis of the hydrodynamic radius showed a single 
population distribution, indicating that the particles were not aggregated, even after their 
functionalization with APTES. After urease attachment, however, a slightly broader peak than 
the one detected for the MSNP-NH2 was observed, indicating a lower monodispersity of the 
particles in terms of hydrodynamic radius, which could be attributed to enzyme conjugation 
(Figure 1b, green). Furthermore, we evaluated the evolution of the surface charge upon the 
modifications of the as-synthesized MSNPs (Figure 1c), denoting negative surface charge for 
the MSNPs (-16.5 ± 1.4 mV, average ± SE, N = 9) and a clear shift to positive surface charge 
after amine modification (43.5 ± 0.4 mV, average ± SE, N = 9). Moreover, we observed a sharp 
decrease on the positively charged surface after the functionalization with urease enzyme (10.3 
± 1.0, average ± SE, N = 9) (Figure 1c). Since urease has an isoelectric point between 5.0 and 
5.2, the observed decrease on the surface charges could be attributed to a successful binding of 
urease enzyme to the particles.[48] The porosity and structure of the nanobots were analyzed by 
Transmission Electron Microscopy (TEM). We observed a clear core-shell structure (Figure 




1f). The presence of urease enzyme on the particles’ surface, as well as the elimination of 
unbound enzymes was analyzed through the use of a colorimetric kit based on reduction of 
copper by proteins’ peptide bonds (Figure S1). [49] 
 
Figure 1. Characterization of the mesoporous silica nanoparticles (MSNP) and further 
modifications to obtain the mesoporous silica nanoparticles functionalized with urease 
(nanobots). SEM micrograph of MSNPs (a). Hydrodynamic radii (b) and surface charge 
evolution (c) upon surface modification of the mesoporous silica nanoparticles with amine 
functional groups and further with urease enzyme. TEM micrographs of MSNP-NH2 (d), 
evidencing the core-shell structure (e) and porosity features (f) of the nanoparticles. 
 
2.2. Motion behavior of urease nanobots 
In the presence of urea, the urease bound to the surface of the nanobots catalyzes the 
decomposition of urea into ammonia and carbon dioxide [(NH2)2CO + H2O → CO2 + 2 NH3]. 
As previous reports have shown, enzymatic catalysis can be used to achieve self-propulsion of 
micro- and nanostructures with different architectures.[22,31,34,36,45] Some nanomotors have been 
fabricated by inducing structural asymmetries such as the creation of Janus particles[31,32] or 
other asymmetric shapes such as polymeric stomatocytes.[34] However, other studies have 
reported an enhanced diffusion for non-Janus spherical polystyrene particles.[50] The actual 




propelling abilities of the nanobots due to the presence of urea was characterized by optical 
tracking of the nanobots trajectories under a range of urea concentrations (Figure 2a). The 
mean-squared displacement (MSD) resulting from the tracked trajectories (Figure 2b) increases 
linearly with time, which is typical of diffusive motion.[53] The effective diffusion coefficient 
(De) was obtained by fitting the MSD curves to equation 1: 
                                                     MSD(Δt) = 4·De·Δt,     (1) 
where De represents the effective diffusion coefficient and Δt represents the time interval.
[54]  
The calculated effective diffusion coefficients are represented in Figure 2c, blue. We further 
confirmed these results by analysing the diffusion coefficients of nanobots in the presence of 
urea by DLS (Figure 2c, green). In both cases a significant increase in the effective diffusion 
coefficient was observed at a 25 mM urea concentration (p < 0.05), which was further increased 
at 50 mM urea, reaching a stabilization. The stabilization of the diffusion coefficient values in 
the presence of increasing concentrations of urea can be explained by the activity kinetics of 
urease. We evaluated the activity of the covalently bound urease on the nanobots surface, over 
the range of urea concentrations studied for motion and we observed that the nanobots present 
Henri-Michaelis-Menten kinetics (Figure 2d), obeying equation 2: 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚+[𝑆]
 ,     (2) 
where Vmax represents the maximum reaction rate, S represents the urea concentration and Km 
represents the Henri-Michaelis-Menten constant.[55] By fitting our data to the equation, we 
found that Km = 4.7 ± 0.5 mM and Vmax = 162.1 ± 1.5 units/mg of urease, where unit is defined 
as the amount of enzyme required to generate 1 μmol of ammonia per minute, at 37 °C and pH 
7.0. These results are in good agreement with values for free enzyme found in literature, 
indicating that urease activity was not affected by its functionalization onto the particles. [56] 
We further characterized the activity of urease enzyme present on the nanobots’ surface over 




of Figure 2d), suggesting that the consumption of substrate and generation of products slows 
the reaction rate over time. 
 
 
Figure 2. Analysis of the motion behavior of urease nanobots. Representative tracking 
trajectories of urease nanobots with different urea concentrations (0 mM – black, 50 mM – 
orange and 100 mM - green) (a) and correspondent mean-squared displacement (MSD) plots 
(b); Effective diffusion coefficient obtained by analyzing the MSD (blue) and by DLS (green) 
of urease nanobots at different urea concentrations (n=20, error bars represent SE) (c). Different 
superscripts denote significant differences among groups with p < 0.05; Enzymatic activity of 
the urease nanobots at different urea concentrations fitted to Henri-Michaelis-Menten equation 
(inset: variation of enzymatic activity of the nanobots with time) (d). 
 
Motivated by the intrinsic presence of salts in physiologically relevant media, we investigated 
the effect of the presence of salts in the surrounding medium on the nanobots’ diffusion 
coefficient, using phosphate buffered saline solution (PBS 1x). We observed different diffusion 
coefficient values between nanobots suspended in water and in PBS (Figure 3a), which could 
be attributed to changes in electrostatic interactions between motors and neighboring surfaces 
driven by the presence of salts.[57] However, the nanobots displayed enhanced diffusion in both 
PBS and water solutions in the presence of urea, where an increase in diffusion coefficient of 




analyzed the nanobots self-propulsion in ionic media by DLS, where a shift on diffusion 
coefficient is observed (Figure 3c).  
 
 
Figure 3. Analysis of motion behaviors of urease nanobots in water and ionic media. 
Characterization of the motion profiles of urease-powered nanobots in ionic media (PBS) and 
in water by optical microscopy and DLS (N=20, error bars represent SE) (a). Different 
superscripts denote significant differences among groups with p < 0.05. Percentage increase in 
diffusion coefficient in the presence of urea, in water and in PBS, error bars represent the error 
calculated by propagating the SE obtained in the measurements (b). Diffusion coefficient 
histogram nanobots in water and PBS obtained by DLS (c). 
 
2.3. Drug loading and release profiles of the urease nanobots 
We investigated the drug loading and releasing capabilities of nanobots in order to determine 
whether their enhanced diffusion due to availability of urea relates with enhanced drug release 
kinetics. First, we investigated the loading capacity of the architecture of the nanobots before 
and after functionalizing with urease enzyme as drug delivery carrier, using Dox as model drug. 
Dox is a chemotherapeutic agent which belongs to the family of anthracyclines and antitumor 
antibiotics, which intercalates between the base pairs in the DNA, preventing replication and 
thereby arresting the cell cycle.[58]  We determined nanobots’ loading capacity and drug 
entrapment efficiency, which represent the drug content and the percentage of drug successfully 
encapsulated in the nanoparticles, respectively, as follows 
   𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (%) =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑒𝑑
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑁𝑎𝑛𝑜𝑏𝑜𝑡𝑠
 ×  100  (3) 
  
  𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝐷𝑟𝑢𝑔 𝑀𝑎𝑠𝑠




Despite a slight loss of Dox mass during the washing process required for functionalization 
with urease, the nanobots retain roughly 10 % (w/w) of drug (Figure 4a). 
Then, we compared the drug release capabilities of enzymatic nanobots in the presence of 
increasing concentrations of fuel with their passive counterparts (Figure 4b and c). We observed 
that the drug release over 24h hours increased according to the presence of urea. A positive 
correlation between the urea concentration and the release profile was found, reaching a 
saturation at 50 mM urea. The amount of Dox released by the nanobots at urea concentrations 
above 50 mM is almost four times higher compared to the one obtained at 0 mM urea (Figure 
4b). These results are in agreement with the motion analysis, since the saturation of motion was 
also found to be 50 mM of urea. We attribute the enhancement of the drug release from the 
mesoporous cavities to the increased diffusion of the nanobots in the presence of urea, and to 
the flow generated through the surface.[33,59]  Since we observed that urease activity decreases 
overtime (Figure 2d), we performed the release experiments collecting aliquots at every time 
point and replenishing the medium with fresh supply of urea. Thus, the slow release rate 
between 6 and 24h, observed for all conditions analyzed, could be explained by the depletion 
of urea from the medium, as well as by the saturation of the solution with Dox, slowing down 
the drug release. 
 
  
Figure 4. Evaluation of MSNP-NH2 and urease nanobots as drug carriers for Dox. a) Loading 
capacity of Doxorubicin on MSNP-NH2 and urease nanobots; b) Release profiles for Dox from 
the nanobots in different urea concentrations (N = 3, error bars represent SE) and c) Release of 





To study whether the changes in the Dox release profiles could be affected by the changes in 
the pH provoked by urease activity, we monitored the pH of the nanobots solution upon the 
addition of urea. For this, we used PBS adjusted to different pH (5, 6, 9 and 10) as the starting 
solutions, and the pH was measured every minute upon the addition of urea. We observed that 
in all cases, the pH changed immediately to 9, indicating the self-buffering properties of the 
system (Figure S3a). To assess if the quick change in pH was the reason underlying the 
enhancement on drug release, we evaluated the release profiles of nanobots in the presence and 
absence of urea, when placed in buffer solutions at pH 9 (Figure S3b). We observed that even 
when the initial solution was stabilized at pH 9, the release of Dox from the urease nanobots 
was significantly enhanced in the presence of urea, indicating that this phenomenon stems from 
nanobots’ surface activity, regardless of the pH change of the surrounding medium. 
2.4. Nanobots’ efficacy as drug delivery vehicles 
Taking advantage of the enhanced Dox release kinetics from active nanobots, we tested 
nanobots’ biocompatibility and efficacy as drug delivery vehicles to human epithelial cervix 
adenocarcinoma HeLa cells. Urease-powered nanobots’ biocompatibility was evaluated by 
using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which 
is a colorimetric method that determines metabolic activity, by assessing the reduction of MTT 
and formation of formazan crystals by viable cells. The nanobots exhibited biocompatibility 
(>80% viable cells) up to a concentration of 0.5 mg/mL (Figure 5a, black), where less than 
70% of the cells remained viable after the 24 hours incubation period. Viability below that value 
would denote cytotoxicity of nanoparticles, as per the FDA’s and ISO’s standards.[60] When 
nanobots were loaded with Dox and incubated with cells (even in the absence of urea) we 
observed a concentration-dependent toxicity trend, which was significantly higher than non-
Dox loaded nanobots in all cases (Figure 5a, blue). A concentration of 4 µg/ml of free Dox is 




shell nanoparticles, we evaluated IC50 resulting that 0.5 mg/ml of passive nanobots 
(concentration of Dox loaded = 48 µg/mL), whereas only 0.05 mg/ml of active nanobots are 
required to obtain the same effect. These results indicate that not all the loaded Dox 
encapsulated in passive nanobots is released or capable of reaching the desired location, i.e. 
inside the cells. Yet, once urea is present in the medium, a more efficient delivery of Dox to the 
cells is achieved, which could be attributed to a faster release of drug to the media, increased 
transport near or inside the cell and increased cell uptake of the nanobots. The exact contribution 
from each effect needs to be investigated in future works. 
Figure 5 b (green columns) shows the anti-cancer effect of Dox-loaded active nanobots, which 
was attributed to the enhanced release of Dox from active nanobots for increasing 
concentrations of urea. Moreover, we observed a sharp decrease in cell viability for bare 
nanobots for concentrations above 10 mM of urea (Figure 5b, black columns). To investigate 
the origin of this low viability, we studied the cytotoxic contribution of fuel and products, we 
evaluated the biocompatibility of urea and ammonia. Urea was found to be biocompatible for 
concentrations up to 400 mM (Figure S5a). Yet, we observed a cytotoxic effect for ammonia 
concentrations higher than 50 mM (Figure S5b), which would correspond to the total 
conversion of 25 mM urea. 
Altogether, these results indicate that, as a matter of comparison, we obtain the same effect on 
cells with at least ten times lower concentration of active nanobots than with passive 
counterparts. We attribute these results to a synergistic effect of the improved Dox release 





Figure 5. Cytotoxicity assays and efficacy testing of the nanobots as drug carriers in the 
presence and absence of urea. Biocompatibility of nanobots (black) up to high concentrations 
and evaluation of its efficacy as Dox carrier (blue) without urea (a); Urea-dependent 
biocompatibility of the urease nanobots (black) and increased efficacy as Dox delivery vehicles 
(green) at 0.05 mg/mL (b) (N=3, error bars represent SE). 
 
As Dox is a fluorescent molecule, we used fluorescence microscopy to monitor its uptake by 
Hela cells (Figure 6a). For this, cells were incubated with 0.05 mg/mL of Dox-loaded nanobots, 
either in the absence or presence of urea (10 mM) during 1, 4, 6 and 24 hours, after which the 
cells were washed with PBS and labeled with wheat germ agglutinin (WGA – membrane, 
green) and Hoescht (nuclei, blue). Next, quantitative imaging analysis of the red fluorescence 
emission within cells (Figure 6b, N = 15) was performed, observing that the fluorescence signal 
increases with time. Moreover, for all the data points analyzed, we observed a higher red 
fluorescence signal within cell cytoplasm when the nanobots were incubated with urea 
compared to the control, as depicted in Figure 6b and in Figure 6c (red channel column). These 
results agree with the findings from the cytotoxicity experiments, where active nanobots lead 






Figure 6. Interaction of Dox-loaded urease nanobots with HeLa cells. Schematic representing 
the cell labeling and imaging acquisition, Cell membranes were marked with wheat germ 
agglutinin (WGA, green), and nuclei were marked with hoescht (blue). red emission comes 
from Dox (a); Dox fluorescence emission quantification in regions within cells, in the absence 




denote significant differences among groups with p < 0.05 (b); Fluorescence imaging of HeLa 
cells and Dox-loaded nanobots (0.05 mg/mL). Scale bars are 20 μm (c). 
 
3. Conclusion 
In summary, we report urease-modified nanobots, composed of mesoporous silica shell, 
capable of loading the anticancer drug Dox, presenting enhanced drug release profiles 
dependent on urea concentration. Furthermore, we demonstrate the nanobots’ self-propulsion 
in ionic media (PBS buffer), which is a crucial ability for its use in biomedical applications. We 
found that in the presence of urea, the active Dox-loaded nanobots exhibit improved effect on 
HeLa cells compared to passive carriers, due to a synergistic effect of improved drug release 
kinetics and ammonia production by the catalytic decomposition of urea. Future work on fuel-
dependent targeting and cell uptake, novel triggered release mechanisms and in situ guidance 
methods, such as the use of pH, thermal or chemical gradients to attract and guide nanomotors 
in vitro and in vivo need to be addressed for the development of smart and self-propelled drug 
delivery vehicles based on enzyme catalysis. 
 
4. Experimental Section ((delete section if not applicable)) 
Materials:  
Ethanol (EtOH, >99%), Methanol (MeOH, >99%), Hydrochloric Acid (37% in water), 
Ammonium Hydroxide (25% in water), Tetraethylorthosilicate (TEOS, 99%), Triethanolamine 
(TEOA, 99%), Cetyltrimethylammonium bromide (CTAB, 99%), 3-
Aminopropyltriethoxysilane (APTES, 99%), Glutaraldehyde (GA, 25% in water), Urease (from 
Canavalia ensiformis, Type IX, powder, 50,000-100,000 units/g solid), Urease Activity Kit, 
Doxorubicin Hydrochloride (Dox, 99.9%), Urea (99.9%), and Dimethyl sulfoxide (DMSO, 
99.9%) were purchased from Sigma-Aldrich. (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), phosphate buffer saline (PBS), and Dulbecco’s Modified 





Transmission Electron Microscopy (TEM) images were captures by a JEOL JEM-2100 
microscope. Scanning Electron Microscopy (SEM) images were captured by a FEI NOVA 
NanoSEM 230 at 5 kV. Hydrodynamic radii and electrophoretic mobility measurements were 
performed using a Wyatt Möbius coupled with an Atlas cell pressurization system. Absorbance 
spectra of Dox, protein quantification and enzymatic activity assays were carried out using an 
Infinite M200 PRO Multimode Microplate Reader. Optical videos were acquired using a Leica 
DMi8 inverted microscope equipped with a 63x water objective. 
 
Synthesis of Solid SiO2 Spheres:  
The solid silica spheres were prepared using the modified Stöber method. [47] Briefly, a solution 
containing EtOH (7 mL), ultra-pure water (10 mL) and ammonium hydroxide (2 mL) was 
stirred for 15 minutes. After, TEOS (6 mL) was added dropwise and the mixture was kept 
stirring for 21 hours. The formed particles were then collected by centrifugation and washed 
with EtOH (3 times, 2348 g, 3.5 minutes). Finally, the spheres were suspended in EtOH and 
aliquots (0.5 mL) were collected, centrifuged, air dried and weighed to determine the 
concentration of the solid SiO2 suspension. 
 
Coating of Mesoporous Silica Shell on Solid SiO2 Spheres: 
Solid silica spheres (60 mg) were suspended in a solution containing water (20 mL), TEOA (40 
mg) and CTAB (75 mg). The solution was heated to 80 °C and TEOS (0.125 mL) was added 
dropwise, while the solution was stirred. The mixture was kept stirring for 2 hours, after which 
it was collected by centrifugation (845 g, 2.5 minutes) and washed with ultra-pure water once. 
Following, the obtained particles were suspended ina solution of MeOH and HCl (30 mL, 
10:0.6) and refluxed at 80 °C for 24 hours. Finally, the particles were collected by centrifugation 




mL) were collected, centrifuged, air dried and weighed to determine the concentration of the 
suspension. 
 
Amine Functionalization of MSNP:  
The obtained MSNP (2 mg mL-1) were then suspended in EtOH:APTES mixture (20:1, v/v) 
and shaken during 24 hours on an end-to-end rotary shaker. After, the particles were collected 
by centrifugation (845 g, 2.5 minutes) and washed in 3 times with EtOH and 3 times with water. 
Aliquots (0.5 mL) were collected, centrifuged, air dried and weighed to determine the 
concentration of the suspension. 
Urease Functionalization of MSNP-NH2:  MSNP-NH2 (2 mg) were washed 3 times with PBS 
1x. After, the MSNP-NH2 were suspended in (0.9 mL) PBS and GA (100 µL, 25% in water) 
was added to the mixture. The mixture was thoroughly vortexed to ensure good dispersion and 
shaken during 2.5 hours on an end-to-end rotary shaker. Then, the particles were collected by 
centrifugation and washed 3 times with PBS. Afterwards, the MSNP-NH2 activated with GA 
were suspended in a solution of PBS containing urease (3 mg mL-1) and mixed end-to-end on 
a rotary shaker for 18 hours. The resulting urease nanobots were collected by centrifugation 
(1150 g, 3.5 minutes) and washed 3 times with PBS. 
 
Dox Loading in MSNP-NH2:  
Aliquots of MSNP-NH2 (1 mg) were suspended in a Dox solution at a concentration of 1 mM 
and vortexed thoroughly to ensure good dispersion. Then, the mixture was incubated during 24 
hours at room temperature, mixing end-to-end on a rotary shaker. The Dox loaded MSNP-NH2 
were then collected by centrifugation (1150 g, 3.5 minutes) and washed 3 times with PBS to 
ensure complete removal of non-loaded drug. The supernatants were kept and analysed by 




Reader, to determine the drug loading capacity and the entrapment efficiency of the MSNP-
NH2. 
 
Dox Loading and Functionalization of MSNP-NH2:  
To obtain Dox loaded nanobots, firstly the MSNP-NH2 (1 mg) are incubated with 1 mM 
solution of Dox (0.5 mL) as mentioned above. After, the particles are washed 3 times with PBS, 
suspended in  PBS (0.9 mL) and  GA (100 µL) was added, to follow the protocol for the 
functionalization of MSNP-NH2 with urease as mentioned above, yielding Dox-loaded urease 
nanobots. 
 
In Vitro Release of Dox from MSNP-NH2 and urease nanobots:  
To evaluate the ability of the nanobots to enhance the release of the drug in the presence of urea, 
Dox-loaded nanobots (2 mg mL-1) were dispersed in solutions of PBS without urea and 
solutions containing different concentrations of urea. To compare the nanobots to the 
conventional MSNP-NH2 carrier, Dox loaded MSNP-NH2 were also placed in PBS. Then, the 
dispersions were placed on a thermomixer at 37 °C with 300 rpm shaking to avoid 
sedimentation and aliquots (100 μL) were collected every hour over the course of 6h and at 24h, 
refreshing the medium at every time point. The aliquots were then analysed by measuring the 
absorbance at 480 nm, using an Infinite M200 PRO Multimode Microplate Reader, to obtain 
the cumulative release profile of each system. 
 
Optical Video Recording of nanobots and Mean-Square-Displacement (MSD) analysis:  
An inverted optical microscope (Leica DMi8) with a 63x water objective was used for the 
observation and video recording of the nanobots movement. An aqueous solution of nanobots 
was placed on a glass slide and thoroughly mixed with the solutions of urea at the desired 




the drifting effect. Videos of 30 s were recorded up to the first 3 minutes after performing the 
mixture to ensure that the analysis is performed under the same conditions. The videos were 
obtained using a Hamamatsu camera at a frame rate of 50 fps, under bright field.  
The videos were then analysed using a Python code to obtain the tracking trajectories. Then, 
the MSD was calculated using the following: 
MSD(Δt) = <(xi(t+ Δt)-xi(t))
2>, (i=2, for two dimensional analysis) 
The diffusion coefficient (De) is afterwards obtained by fitting the data to the following 
equation: 
MSD(Δt) = 4·De·Δt, 
which is valid at small time intervals for small particles with low rotational diffusion. [53] The 
resulting De is obtained by analysing 20 particles per condition and the error represents SE. 
Enzymatic Activity Evaluation: the activity of the covalently bound urease on the nanobots 
surface was evaluated using a commercial kit that determines the concentration ammonia 
generated by the Berthelot method. [61] The nanobots (0.5 mg mL-1) were incubated with a range 
(1, 5, 25, 50 and 100 mM) of concentrations of urea for 10 minutes, to study the effect of urea 
concentration. The enzymatic activity was also investigated over time, by incubating the 
nanobots (0.5 mg mL-1) with the urea solution provided with the kit for varied time periods (2.5 
– 120 minutes).  
 
Hydrodynamic radii and surface charge analysis:  
A Wyatt Möbius coupled with an Atlas cell pressurization system was used to obtain the 
hydrodynamic radii and electrophoretic mobility of the MSNP. The equipment uses a laser with 
532 nm wavelength, with a detector angle of 163.5 °, performing 3 scans over an acquisition 
time of 5 seconds, acquiring light scattering and electrophoretic mobility data simultaneously. 
Each measurement was performed at least 3 times. To analyse the nanobots’ movement by DLS, 




in the DLS. The measurements were repeated to yield 20 data points per condition. The 
diffusion coefficient is obtained directly from the analysis of the scattering data on the 
Dynamics ® software, and the error represented is the SE. 
 
Nanobots and Dox-loaded nanobots cytotoxicity assays:  
Human epithelial cervix adenocarcinoma HeLa cells were cultured in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with Fetal Bovine Serum (10%), L-Glutamine (200 nM) 
and Penicillin-streptomycin (1%), in a 37 °C and 5% CO2 atmosphere, and split every 3 days at 
a 1:4 ratio. For the viability assessment, cells were seeded in 96-well plates at a density of 10 
000 cells per well. After 24 h, the cells were incubated with nanobots or Dox-Loaded nanobots 
at different concentrations for another 24 hours. The MTT was performed according to 
manufacturer’s instructions. Briefly, a working solution of MTT (12 mM) was prepared and 
added to cell culture medium in a ratio of 1:10 and the cells were incubated with it for 4 hours. 
Afterwards, the medium was removed and the formazan crystals formed were dissolved using 
DMSO (50 μL). Absorbance values at 570 nm wavelength were measured using an Infinite 
M200 PRO Multimode Microplate Reader.   
 
Nanobots’ and Dox-loaded nanobots cytotoxicity assays:  
Human epithelial cervix adenocarcinoma HeLa cells were cultured in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with Fetal Bovine Serum (10%), L-Glutamine (200 nM) 
and Penicillin-streptomycin (1%), in a 37 °C and 5% CO2 atmosphere, and split every 3 days at 
a 1:4 ratio. For the viability assessment, cells were seeded in 96-well plates at a density of 10 
000 cells per well. After 24 h, the cells were incubated with  nanobots (0.05 mg mL-1) or Dox-
loaded nanobots in the presence of 1, 5, 25, 50, 100 and 120 mM of urea s for 24 hours. The 





Imaging of HeLa cells with Dox-loaded nanobots:  
Human epithelial cervix adenocarcinoma HeLa cells were cultured in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with Fetal Bovine Serum (10%), L-Glutamine (200 nM) 
and  Penicillin-streptomycin (1%), in a 37 °C and 5% CO2 atmosphere, and split every 3 days 
at a 1:4 ratio. For the viability assessment, cells were seeded in 8-well plates at a density of 15 
000 cells per well. After 24 h, the cells were incubated with Dox-loaded nanobots (0.05 mg mL-
1) with urea (10 mM) and without urea for 1, 4, 6 and 24 hours. After each incubation period, 
the cells were washed with PBS and the membranes were labeled with wheat germ agglutinin 
(WGA) and the nuclei with Hoescht. The cells were imaged in 3D, using an inverted optical 
microscope (Leica DMi8) equipped with a 63x water objective and a galvo stage, coupled with 
filter cubes for Rhodamine, FITC and DAPI. 
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The capability of enzyme-propelled nanomotors to enhance drug delivery is investigated 
in this study. Urease-powered nanomotors show active motion in ionic media and significantly 
improve the release of Doxorubicin in the presence of urea. The synergy between the resulting 
catalytic products and the enhanced drug delivery results in higher cytotoxic effect towards 
HeLa cells.  
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